Genetic testing for enzymes of drug metabolism: Does it have clinical utility for pain medicine at the present time? A structured review

Pain Medicine

Volumn 5, Issue 1, 2004, Pages 81-93

  Fishbain, David A ^a,b,d   Fishbain, Dana ^c   Lewis, John ^a   Cutler, R B ^a,b,d   Cole, Brandly ^a,d   Rosomoff, H L ^a,b,d   Rosomoff, R Steele ^a,b,d  

^a Department of Psychiatry ^*  (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d South Shore Hospital Miami Beach   (United States)

Author keywords

Cytochrome P 450 enzymes; Drug metabolism; Genetic polymorphism; Genomic testing; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ACYLTRANSFERASE; ALCOHOL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DIAZEPAM; IMIPRAMINE; LEVODOPA; LITHIUM; LOCAL ANESTHETIC AGENT; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; NICOTINE; NORTRIPTYLINE; OPIATE; PHENYTOIN; PROCAINAMIDE; PROPRANOLOL; SUXAMETHONIUM; THIOPURINE METHYLTRANSFERASE; TIMOLOL; UNINDEXED DRUG; VENLAFAXINE; WARFARIN;

CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG METABOLISM; ENZYME ASSAY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; PAIN; PHARMACOGENETICS; PHARMACOGENOMICS; RETROSPECTIVE STUDY; REVIEW;

ANALGESICS; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; GENETIC SCREENING; HUMANS; PAIN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS;

EID: 1642485099     PISSN: 15262375     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2004.04007.x     Document Type: Review

References (50)

1. McLeod HL, Evans WE. Pharmacogenomics: Unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001;41:101-21.
2. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001;7:201-4.
3. Vesell ES. Pharmacogenetics perspectives gained from twin and family studies. In: Kalow W, editor. Pharmacogenetics of drug metabolism. Location?: Pergamon; 2000:843-63.
4. Ingelman-Sundberg M. Pharmacogenetics: An opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001;250:186-200.
5. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999;286:487-91.
6. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-6.
7. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA 2000;286:2270-9.
8. Wolf CR, Smith G, Smith RL. Science, medicine, and the future: Pharmacogenetics. BMJ 2000;320: 987-90.
9. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997;37:269-96.
10. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjoqvist F, Spina E, Brockmoller J. CYP2D6 and (YP2C19 genotype-based dose recommendations for antidepressants: A first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001;104:173-92.
11. Dalen P, Dahl ML, Eichelbaum M, Bertilsson L, Wilkinson GR. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics 1999; 9:697-706.
12. Serretti A, Lilli R, Mandelli L, Lorenzi C, Smeraldi E. Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J 2001;1:71-7.
13. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.
14. Sindrup SH, Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995;5: 335-46.
15. Fagerlund TH, Braaten O. No pain relief from codeine. . .? An introduction to pharmacogenomics. Acta Anaesthesiol Scand 2001;45:140-9.
16. A∝6 Pro385Ser substitution and benzodiazepine sensitivity. Am J Psychiatry 1999;156:1447-9.
17. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, Aschauer HN, McCreadie RG, Ohlraun S, Ferrier N, Masellis M, Verga M, Scharfetter J, Rietschel M, Lovlie R, Levy UH, Meltzer HY, Kennedy JL, Steen VM, Macciardi F. Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27:105-19.
18. Collins FS. Shattack lecture - medical and societal consequences of the Human Genome Project. N Engl J Med 1999;341:28-37.
19. Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuchi S, Tashiro N. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Monit 2000;22:230-2.
20. Evans WE, Johnson JA. Pharmacogenomics: The inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001;2:9-39.
21. Zhao LP, Aragaki C, Hsu L, Quiaoit F. Mapping of complex traits by single-nucleotide polymorphisms. Am J Hum Genet 1998;63:225-40.
22. Brookes AJ. The essence of SNPs. Gene 1999; 234:177-86.
23. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000;405:857-65.
24. Kleyn PW, Vesell ES. Genetic variation as a guide to drug development. Science 1998;281:1820-1.
25. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529-37.
26. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52:349-55.
27. Drug interactions. Med Lett Drugs Ther 2003; 45:46-8.
28. Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determinants of codeine induction by rifampin: The impact of codeine's respiratory, psychomotor and mitotic effects. J Pharmacol Exp Ther 1997;281:330-6.
29. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386-9.
30. Mikus G, Somogyi AA, Bochner F, Chen ZR. Polymorphic metabolism of opioid narcotic drugs: Possible clinical implications. Ann Acad Med Singapore 1991;20:9-12.
31. Tyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 1997;7:375-9.
32. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Supplementary material. http://www.sciencemag.org/feature/data/1044449.shl.
33. Spear BB. Pharmacogenetics and antiepileptic drugs. Epilepsia 2001;42(suppl):31-4.
34. Mihara K, Otani K, Suzuki A, Yasui N, Nakano H, Meng X, Ohkubo T, Nagasaki T, Kaneko S, Tsuchida S, Sugawara K, Gonzalez FJ. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite in-chlorophenylpiperazine. Psychopharmacology (Berl) 1997;133:95-8.
35. Mamiya K, Leiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H, Otsubo K, Higuchi S, Tashiro N. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 1998;39:1317-23.
36. Lin K-M. Biological differences in depression and anxiety across races and ethnic groups. J Clin Psychiatry 2001;62(suppl 13):13-9; discussion 20-1.
37. Dahl ML, Sjoqvist F. Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. Ther Drug Monit 2000;22:114-7.
38. Alvan G, Bertilsson L, Dahl ML, Ingelman-Sundberg M, Sjoqvist F. Moving toward genetic profiling in patient care: The scope and rationale of pharmacogenetic/ecogenetic investigation. Drug Metab Dispos 2001;29:580-5.
39. Jibson MD, Tandon R. An overview of antischizophrenic medications. CNS News 2003;13-7.
40. Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit 2 000;22:118-21.
41. Guttmacher AE, Collins FS. Genomic medicine - a primer. N Engl J Med 2002;347:1512-20.
42. Grudzinskas CV, Woosley RL, Payte TJ. The documents role of pharmacogenetics in the identification and administration of new medications for treating drug abuse. Natl Inst Drug Abuse Res Monogr Ser 1996;162:60-3.
43. Tepper SJ. Triptans and the potential for drug interactions. CNS News 2003;39-42.
44. Pianezza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect reduces smoking. Nature 1998;393:750.
45. Tucker GT. Advances in understanding drug metabolism and its contribution to variability in patient response. Ther Drug Monit 2000;22:110-13.
46. Westermeyer J. Fluoxetine-induced tricyclic toxicity: Extent and duration. J Clin Pharmacol 1991; 31:388-92.
47. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: A prospective study. Eur J Clin Pharmacol 1997;51:395-8.
48. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, Martin WL, Hays LR, Wedlund PJ. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996;60:522-34.
49. Lin K-M, Lau JK, Smith R, Antal E, Poland RE. Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers. Psychopharmacology (Berl) 1988;96:365-9.
50. Wedlund PJ, de Leon J, Davis G. Pharmacogenetic testing in the clinic and cost comparisons. In: Proceedings of the VII Stowe Symposium. Stoke Rochford, UK: UK Metabolism Group; July 1999.